Table 1.
Summary statistics of density measures at baseline (T0) and year 1 (T1) in analysis sample A (all women included in the study)
| Tamoxifen | No tamoxifen | ||||||
|---|---|---|---|---|---|---|---|
| N (unk%) | Median (IQR, range) | Mean (SD*) | N (unk%) | Median (IQR, range) | Mean (SD) | ||
| Visual % blinded | |||||||
| Baseline | 125 (1%) | 25.0 (15.0–45.0, 0.0–90.0) | 32.0 (21.7) | 171 (1%) | 30.0 (15.0–47.5, 0.0–80.0) | 31.6 (20.6) | |
| T1 | 98 (1%) | 20.0 (10.0–40.0, 0.0–90.0) | 26.0 (18.8) | 122 (2%) | 30.0 (15.0–50.0, 0.0–90.0) | 33.5 (22.7) | |
| T1–T0 | 94 (1%) | −5.0 (−13.8–0.0, −45.0–20.0) | −6.4 (9.8, −0.66) | 112 (2%) | 0.0 (−5.0–5.0, −25.0–30.0) | −0.2 (9.6) | |
| Visual % unblinded | |||||||
| Baseline | 98 (22%) | 25.0 (15.0–45.0, 0.0–95.0) | 31.3 (20.5) | 0 (100%) | |||
| T1 | 96 (3%) | 20.0 (10.0–30.0, 0.0–90.0) | 23.4 (18.0) | 0 (100%) | |||
| T1–T0 | 92 (3%) | −5.0 (−12.8–5.0, −35.0–25.0) | −8.7 (9.4, −0.92) | 0 (100%) | |||
| Stratus % | |||||||
| Baseline | 126 (0%) | 37.8 (13.5–56.8, 0.2–77.2) | 34.6 (23.6) | 172 (0%) | 42.4 (9.1–58.0, 0.1–75.3) | 36.2 (24.3) | |
| T1 | 99 (0%) | 27.6 (4.7–45.5, 0.1–67.4) | 27.2 (21.3) | 124 (0%) | 42.7 (12.7–57.2, 0.1–71.0) | 36.1 (23.5) | |
| T1–T0 | 95 (0%) | −6.2 (−12.9–0.9, −56.5–12.0) | −7.8 (9.7, −0.81) | 114 (0%) | −0.1 (−3.5–1.5, −27.7–56.5) | −0.2 (8.3) | |
| Stratus DA | |||||||
| Baseline | 126 (0%) | 47.8 (17.2–64.7, 0.6–167.6) | 46.5 (34.8) | 172 (0%) | 44.4 (16.9–67.3, 0.3–211.2) | 48.3 (39.3) | |
| T1 | 99 (0%) | 29.9 (9.1–47.7, 0.2–128.1) | 34.2 (28.9) | 124 (0%) | 42.2 (20.2–69.9, 0.3–181.5) | 48.7 (38.5) | |
| T1–T0 | 95 (0%) | −10.8 (−19.2–3.3, −75.5–20.3) | −13.0 (13.7, −0.95) | 114 (0%) | −1.0 (−6.3–3.2, −54.4–108.3) | −0.5 (14.3) | |
| Densitas % | |||||||
| Baseline | 126 (0%) | 41.0 (32.0–49.5, 12.0–73.0) | 41.2 (12.9) | 172 (0%) | 42.0 (32.0–49.0, 10.0–72.0) | 41.1 (12.3) | |
| T1 | 99 (0%) | 38.0 (29.0–47.0, 13.0–66.0) | 37.7 (12.3) | 124 (0%) | 40.0 (34.0–50.2, 13.0–70.0) | 41.4 (12.0) | |
| T1–T0 | 95 (0%) | −5.0 (−8.0–1.5, −21.0–34.0) | −4.3 (7.0, −0.62) | 114 (0%) | 0.0 (−3.0–3.0, −21.0–25.0) | −0.4 (5.9) | |
| Densitas DA | |||||||
| Baseline | 126 (0%) | 44.0 (32.2–57.0, 15.0–131.0) | 47.5 (22.3) | 172 (0%) | 41.5 (31.0–57.0, 19.0–162.0) | 47.3 (24.0) | |
| T1 | 99 (0%) | 36.0 (27.5–49.5, 15.0–143.0) | 41.4 (20.9) | 124 (0%) | 43.0 (33.0–55.2, 19.0–157.0) | 48.5 (23.3) | |
| T1–T0 | 95 (0%) | −6.0 (−11.0–3.0, −35.0–103.0) | −5.8 (14.0, -0.42) | 114 (0%) | 0.0 (−3.0–4.0, −42.0–33.0) | 0.1 (8.2) | |
| Volpara % | |||||||
| Baseline | 126 (0%) | 8.6 (5.4–15.7, 2.2–31.4) | 11.0 (6.8) | 172 (0%) | 9.5 (5.7–14.1, 2.2–29.0) | 10.7 (6.2) | |
| T1 | 99 (0%) | 7.5 (4.7–13.0, 2.1–27.8) | 9.3 (5.8) | 124 (0%) | 9.1 (5.7–15.4, 2.1–28.2) | 11.0 (6.2) | |
| T1–T0 | 95 (0%) | −0.9 (−2.3–0.2, −9.8–4.6) | −1.4 (2.5, −0.56) | 114 (0%) | 0.0 (−0.9–0.9, −13.9–10.4) | −0.2 (2.8) | |
| Volpara DV | |||||||
| Baseline | 126 (0%) | 61.4 (43.9–86.2, 17.6–189.9) | 69.4 (36.2) | 172 (0%) | 62.1 (40.6–89.1, 14.4–246.8) | 70.7 (38.8) | |
| T1 | 99 (0%) | 49.7 (35.9–67.0, 17.5–173.1) | 55.3 (27.3) | 124 (0%) | 57.5 (41.1–85.2, 11.3–196.5) | 67.7 (38.4) | |
| T1–T0 | 95 (0%) | −11.0 (−21.6–2.7, −74.2–26.5) | −14.2 (16.3, −0.87) | 114 (0%) | −2.5 (−11.3–4.5, −83.5–51.0) | −3.8 (18.7) | |
| NN-VAS % | |||||||
| Baseline | 126 (0%) | 41.1 (29.7–54.5, 7.1–76.8) | 42.0 (16.3) | 172 (0%) | 43.8 (31.1–53.5, 8.4–76.0) | 42.5 (16.1) | |
| T1 | 99 (0%) | 37.4 (23.6–47.0, 5.3–73.7) | 36.9 (15.0) | 124 (0%) | 44.4 (31.2–54.2, 6.8–78.0) | 42.5 (16.6) | |
| T1–T0 | 95 (0%) | −5.3 (−8.8–2.0, −24.2–18.1) | −5.3 (5.8, −0.90) | 114 (0%) | −0.7 (−3.6–1.0, −19.8–31.8) | −1.1 (6.0) | |
DA dense area, DV dense volume, IQR inter-quartile range, SD standard deviation, unk unknown
*T1–T0 for tamoxifen group statistic is mean (SD, mean/SD)